BusinessNews.ph

• 3-y deal for GI Lite™, low GI white bread for US, Canada & Mexico markets
• 165 tons for US$1.9m 1st year, 220 tons for US$2.5m, 2nd, 3rd each year
• The partners co-developed bread product, validation by University of Sydney

Holista Colltech Limited (ASX: HCT, “Holista”) and U.S. subsidiary, Holista Foods Inc., have entered into an agreement with leading U.S. breadmaker, Costanzo’s Bakery, Inc. (“Costanzo’s”), to manufacture the world’s lowest Glycaemic Index (GI) clean label white bread using all-natural ingredients.

Under the exclusive three-year Licence and Commercialisation agreement, Costanzo’s will purchase Holista’s GI Lite™ Bread Premix which will be used to produce a range of healthier breads for the USA, Canada and Mexico.

Costanzo’s, a third-generation Italian baker founded 87 years ago in New York City, produces and supplies bread products across the USA and Canada to supermarkets and other retail outlets.

The healthier bread was jointly developed by Holista and Constanzo’s. The University of Sydney tested and validated this bread in July 2020 to have a GI reading of 46, which compares with GI readings of over 70 for most white breads.

Holista believes this is the world’s lowest GI reading for clean-label (free of chemicals) white breads worldwide. This latest bread formula is significantly lower than the reading of 53 validated by the University of Sydney in 2016.

GI Lite™ is a patented formula made from a blend of okra, barley, lentils and fenugreek. When mixed with white flour, it lowers the GI reading of the final product without compromising taste, mouth-feel or food production methods.

Under the agreement, Holista will supply 165 tons of worth valued at US$1.9 million in the first year of the contract with Constanzo’s. Over the next two years, shipment will increase to 220 tons (valued at US$2.2 million) annually.

“There is a large and untapped market for clean-label, all-natural, low-GI white bread and we are pleased to be able to offer our customers such a unique and healthy product,” said Costanzo’s CEO, Angelo Costanzo III.

“We are confident about the success of the GI Lite™ breads due to its superior taste and mouthfeel, which cannot be matched by other low GI breads in the market as they use chemicals and other artificial ingredients.”

GI measures food products, ranking them between 0-100 according to the impact on blood sugar levels. The lower the GI, the more time it takes for glucose to be digested and absorbed into the bloodstream. Higher GI causes a spike in blood sugar levels, contributing to diabetes.

Dr Rajen Manicka, CEO of Holista, an Australia Securities Exchange (“ASX”) listed company, commented:
“This is a breakthrough agreement for the North American market and we expect this to spur interest in other markets. We are excited to be bringing a healthier and better-tasting white bread product to the world, and we are currently pursuing opportunities in other countries.”

“Providing the world’s lowest low GI healthy clean label white bread has been our goal and vision,” said Nadja Piatka, CEO of Holista Foods which is based in Buffalo, New York. “Costanzo’s is a perfect partner to bring this important mission to fruition.”

Holista Foods won the Award of Excellence under “Low Glycaemic Pasta” category for its spaghetti and linguine in the 2019 U.S.A. Taste Championships. Holista has also developed low-GI versions of flat-breads such as chappatis and tortillas.

About Holista Colltech Limited

Holista Colltech Ltd (“Holista”) is a natural wellness company, that has the following main divisions:
– Dietary supplements
– Food Ingredients
– Ovine collagen
– Infection Control Solutions

Holista has a global collaboration with Global Infection Control Consultants LLC to use Path-Away®, a plant-based solution that is proven to kill a broad spectrum of microbes. The all-natural alcohol-free active ingredient is used in Holista’s range of sanitising products under the NatShield™ brand.

Listed on the Australian Securities Exchange (“ASX”), Holista researches, develops, manufactures and markets health style products. Holista’s suite of ingredients includes low GI baked products, reduced-sodium salts, low-fat fried foods and low-calorie sugar without compromising taste, odour and mouthfeel. Holista also produces sheep (ovine) collagen using patented extraction methods. For more information on Holista, please visit https://www.holistaco.com/

About Costanzo’s Bakery Inc.

Costanzo’s Bakery (“Costanzo”) started in a small shop in 1933 along the Niagara River delivering Italian breads to “mom and pop” grocery stores throughout Buffalo, NY. As the business grew, and with the advent of the Supermarket, Costanzo’s bread was soon found in every store throughout the region. In 1977, Angelo Costanzo’s sons took over the bakery and eventually moved into a new location. As the business grew, the natural progression was to expand into the national marketplace by developing a line of frozen, fully-baked sub rolls and round rolls. This was the beginning of Costanzo’s Bakery, Inc. Today, with the third generation of Costanzo’s at the helm, the bakery services retail outlets and local routes in the Buffalo/Niagara region, as well as a national distribution network in the Foodservice, Deli/Bakery, and Retail businesses, with all products being produced and delivered from its bakery in Cheektowaga, NY. For more information on Costanzo, please visit https://costanzosbakery.com

About Holista Foods, Inc.

Holista Foods is dedicated to developing and delivering clean label ingredients, finished food products and recipe development. The company specializes in next-generation food research and development for improved taste and nutritional value. Under the leadership of Nadja Piatka, Holista Foods is embracing a philosophy of providing great tasting, nutritional food products that will be readily available to all consumers. Nadja’s original passion for providing healthy food products to consumers has carried over to low GI food innovations for an even healthier nutritional outcome.

With the successful launch of the world’s first low glycaemic noodles, spaghetti and linguine and low glycaemic bread, the company is working on new low glycaemic products.

Holista Foods is 74%-owned by LiteFood Inc of US and 26%-owned by Nadja Piatka and Nadja Foods. LiteFoods Inc is 53%-owned by Holista. Holista Foods, Inc. is based in Buffalo, NY. For more information on Holista Foods, Inc., please visit www.holistafoods.com

For further information, please contact:
Corporate Affairs & Business Opportunities
Corporate Matters: investor@holistaco.com
General Enquiries: enquiries@holistaco.com

Global Investor relations and media enquiries:
WeR1 Consultants Pte Ltd
E: holista@wer1.net
M: +65 673 74 844

Taiwan’s biotech is gradually emerging. During the COVID-19 epidemic, we had a chance to see the advanced medical equipment and the effective preventive measures taken at the community level. The government took precautions, while private companies were introducing high-quality biotechnology products made in Taiwan. In the post-pandemic period, the world may become more sensitive to the need to strengthen prevention and improve medical treatment. The Taiwan Greenyn Group has been developing health foods for the global market for over 20 years. On Sept. 8, Greenyn Biotechnology, a member of the Greenyn Group, presented clinical results for Insumate®–Patented Peptide Sequence: mcIRBP-19.

Mr. Wu Chia Feng, Chairman of Taiwan Greenyn Group, pointed out, “Greenyn Biotechnology was established in 2012 as a subsidiary of Taiwan Greenyn Corporation. The company has many experts in medical and food biotechnology. Greenyn Biotechnology has invested heavily in research and development over the years, and finally, their products are receiving international recognition. The main goal of the company is to improve the quality of life for all people through preventive medicine.”

Among chronic diseases, the health problems caused by diabetes are particularly pervasive, and growing at an alarming rate. According to data released by the International Diabetes Federation, 463 million people were living with diabetes at the end of 2019, with related medical expenses of US$760 billion. Each year, 4.2 million people die from diabetes and its complications. With insufficient action, these numbers will continue to spiral. China, Southeast Asia, and the Western Pacific Region account for 35% of all diabetics, one third of all confirmed cases.

As the company was being established nearly10 years earlier, researchers were already conducting trials on animal and human cells, and discovering that mcIRBP-19 had the potential to regulate blood sugar. Greenyn Biotechnology partnered with Chung Shan Medical University Hospital to conduct clinical trials on diabeties and functional food therapies. Professional medical teams worked tirelessly to carry out these trials, which finally obtained double approval from the Institutional Review Board (IRB). Greenyn Biotechnology confirmed on a scientific basis that a highly active extract from bitter gourd correlated with human insulin receptors. Greenyn Biotechnology called the extract “Patented Peptide Sequence: mcIRBP-19”, and the brand, “Insumate®.”

Dr. Yang Yi-Tien of Chung Shan Medical University Hospital conducted the randomized double-blind clinical trial, which confirmed that Patented Peptide Sequence: mcIRBP-19 had outstanding results on diabetic patients who undertook adjuvant therapy. The trial was conducted on 29 diabetics who were long-term patients of hypoglycemic drugs of less effectiveness. Without breaking routine drug therapy, the diabetic trials were conducted for 3 months, concluding that fasting blood sugar and glycosylated hemoglobin in the therapy group were significantly reduced. Their liver function, kidney function, and hemoglobin remained unchanged. There were no side effects of hypoglycemia and allergic gastrointestinal discomfort, which usually occur to users of oral hypoglycemic drugs. As for the control group, there was no noticeable difference. The clinical results are being submitted to an International Journal.

The unique structure of Patented Peptide Sequence: mcIRBP-19 allows for use as a pathogenic target. These results have been published in the Science Citation Index (SCI). Dr. Hsu Pang-kuei, chief of research and development at Greenyn Biotechnology, has been conducting research for more than a decade. “After many years, we discovered that mcIRBP-19 has a hypoglycemic effect on insulin-like biological activities and can bind insulin receptors. Without stimulating insulin secretion, mcIRBP-19 can participate in the body’s carbohydrate metabolism and regulate blood sugar. Besides insulin, mcIRBP-19 has been scientifically confirmed as a natural product able to bind insulin receptors to regulate blood sugar.” said Dr. Hsu. Yet another clinical trial reported that 142 diabetics who were long-term users for hypoglycemic drugs took mcIRBP-19 for 3 months, and their blood sugar indexes and glycosylated hemoglobin were well regulated. These results were published in the world-famous Journal of Nutrition.

Insumate®: mcIRBP-19 functions to regulate blood sugar, processing at low temperatures with high activity, and passing toxicity tests. This biotechnology innovation has helped Greenyn Biotechnology in obtaining 19 patent certificates and recognition from the world’s largest discovery exhibitions, the Discovery and New Products Expo (INPEX) in Pittsburgh, Pa, USA; International Discovery Exhibition of Geneva, Switzerland; and the Nuremberg International Expo (IENA) in Germany. An extensive summary of mcIRBP-19 has also been published in the Scientific Citation Index (SCI). Presently, many well-known international process manufacturers use ingredients provided by Greenyn Biotechnology to produce health foods. Greenyn Biotechnology attributes these achievements to its utmost efforts in recent years.

As Dr. Hsu pointed out, “There are many similar products on the market, called bitter melon peptide or peptide-related peptide. But under professional tests, they are only hydrolyzed water or bitter watermelon extract. They do not contain any ingredients able to regulate blood sugar as Insumate®: mcIRBP-19. The most important thing is that strictly selected ingredients must be certified and scientifically validated locally and internationally. Only after rigorous quality testing can the product achieve its medical purpose.”

Mr. Yang Lihua, Secretary General of the Taiwan Functional Food Industry Association, said, “The Taiwan Greenyn philosophy is to rigorously pursue innovative R&D in precision medicine. We define precision medicine as a combination of prevention, healthcare, and clinical testing. Even with the support of scientific testing, improving medicine into a method of prevention takes a long time. With incredible investment and perseverance, Taiwan Greenyn has become a model for various Taiwanese industries due to continuous innovation. They have improved Taiwanese medicine into precision medicine.”

To ensure excellent product quality, Greenwyn Biotechnology has developed a comprehensive, one-stop service solution in areas such as product development, market positioning, formula design, packaging design, manufacturing design, clinical planning, marketing planning and customer service. Greenyn is dedicated to creating new futures for tomorrow’s healthy lifestyles.

Watch the “Insumate®–Natural Patented Peptide Sequence: mclRBP-19” video at: https://www.youtube.com/watch?v=1RgZk1ZPCKo&t=462s

Media Contact
Greenyn Biotechnology Co. Ltd.
Phone: +886-968-199-656
Contact: Nick Chen
Email: info@greenyn.com.tw
http://en.greenynbio.com/index.php